Insider Selling: Zynex, Inc. (NASDAQ:ZYXI) CEO Sells 2,000 Shares of Stock

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of Zynex stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $8.67, for a total transaction of $17,340.00. Following the completion of the transaction, the chief executive officer now owns 14,619,350 shares in the company, valued at approximately $126,749,764.50. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Thomas Sandgaard also recently made the following trade(s):

• On Wednesday, November 6th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.82, for a total transaction of $17,640.00.
• On Friday, November 1st, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.63, for a total transaction of $17,260.00.
• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The shares were sold at an average price of $8.92, for a total transaction of $17,840.00.

Zynex Stock Up 10.2 %

Zynex stock traded up $0.85 during mid-day trading on Wednesday, hitting $9.21. 243,942 shares of the company’s stock were exchanged, compared to its average volume of 172,001. Zynex, Inc. has a 1-year low of $7.15 and a 1-year high of $13.77. The stock has a 50 day moving average of $8.14 and a two-hundred day moving average of $9.00. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66. The stock has a market cap of $293.34 million, a P/E ratio of 61.40 and a beta of 0.53.

Zynex (NASDAQ:ZYXI) last issued its quarterly earnings data on Thursday, October 24th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The business had revenue of $49.97 million for the quarter, compared to analyst estimates of $50.83 million. During the same quarter in the prior year, the firm posted $0.10 EPS. The firm’s revenue for the quarter was up .1% on a year-over-year basis. As a group, analysts anticipate that Zynex, Inc. will post 0.2 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on ZYXI shares. HC Wainwright increased their price objective on Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, October 25th. Royal Bank of Canada lowered their price target on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th.

Hedge Funds Weigh In On Zynex

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZYXI. Vanguard Group Inc. lifted its stake in shares of Zynex by 0.5% in the first quarter. Vanguard Group Inc. now owns 1,187,089 shares of the company’s stock worth $14,684,000 after buying an additional 6,097 shares during the last quarter. Millennium Management LLC raised its holdings in Zynex by 66.5% in the 2nd quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock worth $2,769,000 after acquiring an additional 118,615 shares during the period. Royce & Associates LP lifted its position in Zynex by 9.2% during the 3rd quarter. Royce & Associates LP now owns 257,291 shares of the company’s stock worth $2,099,000 after acquiring an additional 21,781 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Zynex by 1.6% during the second quarter. Bank of New York Mellon Corp now owns 192,832 shares of the company’s stock valued at $1,797,000 after acquiring an additional 2,954 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Zynex by 68.7% in the second quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock valued at $1,769,000 after purchasing an additional 77,300 shares during the last quarter. Institutional investors and hedge funds own 29.68% of the company’s stock.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.